Spots Global Cancer Trial Database for The Effect of Individualized Precision Therapy Programs in Patients With BTC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: The Effect of Individualized Precision Therapy Programs in Patients With BTC

Official Title: The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer

Study ID: NCT02943031

Conditions

Biliary Tract Neoplasms

Interventions

Individualized Precision Therapy Programs

Study Description

Brief Summary: This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled in this study. The samples of biliary tract tumors will be collected. Genome sequencing, mini-PDX and PDX will be performed according to the requirement of individualized precision therapy programs. Suitable drugs will be chose according to drug screening results. OS and PFS will be compared with traditional chemotherapy to evaluate the effect of individualized precision therapy programs.

Detailed Description: In this prospective cohort study, patients who are eligible for inclusion criteria will enroll in the study. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification, and then to develop individualized precise treatment programs. The investigators hope to achieve the following objectives: ① Through the establishment of Individualized Precision Therapy Programs to improve the overall survival of bile duct malignancy (BTC)； ② To study the molecular typing of the prognosis of biliary malignancy; ③ To construct a database of BTC gene bank, as well as for drug screening information.